Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.

史密斯+内皮尔（Smith+Nephew，伦敦证交所代码：SN，纽约证交所代码：SNN），全球医疗技术公司，宣布任命阿贾伊·丹卡尔博士（Ajay Dhankhar, PhD）为首席企业发展与战略官，即时生效。阿贾伊将向首席执行官迪帕克·纳特（Deepak Nath）汇报，并加入史密斯+内皮尔执行委员会。

As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.

作为资深管理顾问和投资银行家，Ajay曾为全球一些领先的医疗保健公司的首席执行官和董事会提供咨询，帮助实现显著的股东价值。

Ajay’s experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D.

阿贾伊拥有25年在麦肯锡公司的经验，他曾担任高级合伙人，并担任过多个领导职务，包括全球跨行业战略主管、全球生命科学战略与并购主管以及全球生命科学研究与开发主管。

Following that, Ajay served as a Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd (NYSE: LAZ) where he was the Global Head of Medical Technology, Diagnostics and Tools. More recently, Ajay founded and led Bluish Capital, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets.

此后，Ajay曾在拉扎德有限公司（纽约证券交易所代码：LAZ）的金融咨询医疗保健集团担任董事总经理，期间他担任全球医疗技术、诊断和工具主管。最近，Ajay创立并领导了Bluish Capital，这是一家专注于部署成长型资本以支持高质量、近期获得FDA批准资产的战略和金融咨询公司。

.

。

Ajay has bachelor’s degrees in Physics and Computer Science from Angelo State University, and both a master’s degree and a doctorate in Molecular Biophysics and Biochemistry from Yale University.

阿贾伊拥有安吉洛州立大学的物理学和计算机科学学士学位，并且拥有耶鲁大学的分子生物物理与生物化学硕士和博士学位。

Deepak Nath, Chief Executive Officer, commented: “Ajay’s unique blend of scientific rigor, strategic insight, business development, integrations, and operational excellence, combined with his entrepreneurial leadership style, makes him exceptionally well-suited to help shape our future. We are pleased to have him join our leadership team at this exciting time for the company.”.

德帕克·纳特首席执行官评论道：“阿贾伊独特的科学严谨性、战略洞察力、业务发展、整合能力和卓越的运营能力，加上他创业型的领导风格，使他特别适合帮助塑造我们的未来。我们很高兴在他加入公司领导团队，共同见证这一令人兴奋的时刻。”

Enquiries

查询

Investors

投资者

Andrew Swift

安德鲁·斯威夫特

+44 (0) 1923 477433

+44 (0) 1923 477433

Smith+Nephew

史密斯和内腓 компания

Media

媒体

Charles Reynolds

查尔斯·雷诺兹

+44 (0) 1923 477314

+44 (0) 1923 477314

Smith+Nephew

史密斯＋内腓尔斯

Susan Gilchrist / Ayesha Bharmal

苏珊·吉尔克里斯特 / 艾莎·巴尔马尔

+44 (0) 20 7404 5959

+44 (0) 20 7404 5959

Brunswick

不伦瑞克

About Smith+Nephew

关于施乐辉

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management..

史密斯与内修是一家专注于修复、再生和替换软硬组织的医疗技术公司。我们通过使用技术消除生活中的限制，来恢复人们的身体和自信。我们将此宗旨称为“无限生命”。我们17,000名员工每天都在践行这一使命，通过我们卓越的产品组合以及在骨科、运动医学及耳鼻喉科和先进伤口管理三大全球业务部门中发明和应用新技术，为患者的生活带来改变。

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

史密斯和内修公司于1856年在英国赫尔成立，目前我们在约100个国家开展业务，并在2024年实现了58亿美元的年销售额。史密斯和内修是富时100指数成分股（伦敦证交所：SN，纽约证交所：SNN）。“集团”和“史密斯和内修”术语用于指代史密斯和内修公司及其合并子公司，除非上下文另有要求。

.

。

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

有关Smith+Nephew的更多信息，请访问www.smith-nephew.com，并在X、LinkedIn、Instagram或Facebook上关注我们。

Forward-looking

前瞻性

Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements.

本文件可能包含前瞻性陈述，这些陈述可能会被证实准确，也可能不会。例如，有关预期收入增长和交易利润率、市场趋势及我们的产品线的陈述均为前瞻性陈述。诸如“目标”、“计划”、“意图”、“预期”、“定位良好”、“相信”、“估计”、“预计”、“针对”、“考虑”等词语及相关表达通常用于识别前瞻性陈述。

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology.

前瞻性声明涉及已知和未知的风险、不确定性以及其他可能导致实际结果与这些声明所表达或暗示的内容存在重大差异的重要因素。对于施乐辉（Smith+Nephew）而言，这些因素包括：欧洲和中东的冲突；我们所服务市场的经济和金融状况，特别是那些影响医疗服务提供者、支付方和客户的情况；传统和创新医疗设备的价格水平；医疗技术的发展；监管批准、报销决策或其他政府行为；产品缺陷或召回，或其他与质量管理体系相关的问题，或未能遵守相关法规；与专利或其他索赔相关的诉讼；法律和财务合规风险及相关调查、补救或执法行动；对我们供应链或运营，或我们供应商的供应链或运营造成的中断；对合格人员的竞争；战略性举措，包括收购和处置，以及我们在尽职调查、估值和整合被收购业务中的成功程度；因交易或为适应市场发展而对我们业务计划或组织架构进行的其他变更可能引发的干扰；与医疗专业人士的关系；对信息技术的依赖。

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

◊ Smith+Nephew的商标。某些标志已在美国专利和商标局注册。